Skip to main content

Advertisement

SpringerLink
Log in

Alternatives for the Intensive Follow-Up After Curative Resection of Colorectal Cancer. Potential Novel Biomarkers for the Recommendations

  • Review
  • Published:
Pathology & Oncology Research

Abstract

Early diagnosis of recurrence and metastasis of colorectal cancer following surgery of curative intent is of vital importance in terms of survival and quality of life. The consistent implementation of appropriate patient follow-up strategy is therefore essential. Debates over the methodology, evaluation and strategy of follow-up have been known for many years, and continue today. By introducing several follow-up models, the present paper offers different options featuring certain individual, national and international, conceptual and financial aspects. Colorectal cancer is an important public health concern due to its destructive nature and frequency, it is therefore essential to develop new monitoring strategies, involving new biomarkers and extensive clinical validation. Since the recurrence rate is very high in high-risk patients, the improvement of individual patient risk estimates and the utilization of a corresponding follow-up model require broad international co-operation and common practice, along with the determination of optimal levels of evidence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

ESMO:

European Society for Medical Oncology

ESCRS:

American Society of Colon and Rectal Surgeons

NCCN:

National Comprehensive Cancer Network

SGG:

Schweizerischen Gesellschalt für Gastroenterologie

ASCO:

American Society of Clinical Oncology

CRC:

Colorectal cancer

JSCCR:

Japanese Society for Cancer of the Colon and Rectum

FIT:

Fecal immunochemical testing

References

  1. Bray F, Sankila F, Ferlay J et al (2002) Estimates ef cancer incidence and mortality in Europe in 1995. Eur J Cancer 38:99–166

    Article  CAS  PubMed  Google Scholar 

  2. Ferlay J, Autier P, Boniol M et al (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581–592

    Article  CAS  PubMed  Google Scholar 

  3. Ottó S (2003) Cancer epidemiology in Hungary and the Béla Johan National Program for the decade of health. Pathol Oncol Res 2:126–130

    Article  Google Scholar 

  4. Yang L, Fujimoto J, Qiu D et al (2010) Trends in cancer mortality in the elderly in Japan, 1970–2007. Ann Oncol 21:389–396

    Article  CAS  PubMed  Google Scholar 

  5. Bosetti C, Levi F, Rosato V et al (2011) Recent trends in colorectal cancer mortality in Europe. Int J Cancer 129:180–191

    Article  CAS  PubMed  Google Scholar 

  6. Malvezzi M, Bertuccio P, Levi F et al (2012) European cancer mortality predictions for the year 2012. Ann Oncology 23:1044–1052

    Article  CAS  Google Scholar 

  7. Verdecchia A, Francisci S, Brenner H et al (2007) Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol 8:784–796

    Article  PubMed  Google Scholar 

  8. Majek O, Gondos A, Jansen L et al (2012) Survival from colorectal cancer in Germany in the early 2 Ist century. Br J Cancer 106:1875–1880

    Article  CAS  PubMed  Google Scholar 

  9. Rachet B, Woods LM, Mitry E et al (2008) Cancer survival in England and Wales at the end of the 20th century. Br J Cancer 99:S2–S10

    Article  PubMed  Google Scholar 

  10. Aslam MI, Taylor K, Pringle JH et al (2009) MicroRNAs are novel biomarkers of colorectal cancer. Br J Surg 96:702–710

    Article  CAS  PubMed  Google Scholar 

  11. La Vecchia C, Bosetti C, Lucchini F et al (2010) Cancer mortality in Europe, 2000–2004, and overview of trends since 1975. Ann Oncol 21:1323–1360

    Article  PubMed  Google Scholar 

  12. Tusnády G, Gaudi I, Rejtő L et al (2008) Survival chances of Hungarian cancer patients in the National Cancer Registry. Hungarian Oncol 52:339–349

    Google Scholar 

  13. Olesen F, Hansen RP, Vedsted P (2009) Delay in diagnosis: the experience in Denmark. Br J Cancer 101:55–58

    Article  Google Scholar 

  14. Schmoll HJ, Van Cutsem E, Stein A et al (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23:2479–2516

    Article  CAS  PubMed  Google Scholar 

  15. Baca B, Beart RW, Etzioni DA (2011) Surveillance after colorectal cancer resection: a systematic review. Dis Colon Rectum 54:1036–1048

    Article  PubMed  Google Scholar 

  16. Levin B, Liberman DA, McFarland B et al (2008) American Cancer Society Colorectal Cancer Advisory Group. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multy-Society Task Force on colorectal cancer, and the American College of Radiology. Gastroenterology 134:1570–1595

    Article  CAS  PubMed  Google Scholar 

  17. Dunn BK, Wagner PD, Anderson D et al (2010) Molecular markers for early detection. Semin Oncol 37:224–242

    Article  CAS  PubMed  Google Scholar 

  18. Diamandis EP (2010) Cancer Biomarkers: can we turn recent failures into success? J Natl Cancer Inst 102:1462–1467

    Article  CAS  PubMed  Google Scholar 

  19. Bertagnolli MM (2009) The forest and the trees:pathways and proteins as colorectal cancer biomarkers. J Clin Oncol 27:5866–5867

    Article  PubMed  Google Scholar 

  20. Jung Y, Lee S, Choi H-S et al (2011) Clinical validation of colorectal cancer biomarkers identified from bioinformatics analysis of public expression data. Clin Cancer Res 17:700–709

    Article  CAS  PubMed  Google Scholar 

  21. Gutman S, Kessler LG (2006) The US Food and Drug Administration perspective on cancer biomarker development. Nature Rev/Cancer 6:565–571

    CAS  Google Scholar 

  22. McShane LM, Hayes DF (2012) Publication of tumos marker research result: the necesity for complete and transparent reporting. J Clin Oncol 30:4223–4232

    Article  PubMed  Google Scholar 

  23. Labianca R, Nordlinger B, Beretta GD et al (2010) Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 21(Suppl 5):v70–v77

    Article  PubMed  Google Scholar 

  24. Griesenberg D, Nürnberg R, Bahlo M et al (1999) CEA, TPS, CA 19–9 and CA 72–4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer. Anticancer Res 19:2443–2450

    CAS  PubMed  Google Scholar 

  25. Hohnbec JRL, Topolcan O, Pikner R et al (2000) The significance of CEA, CA 19–9 and CA 72–4 in the detection of colorectal carcinoma recurrence. Anticancer Res 20:5237–5244

    Google Scholar 

  26. Lane JM, Chow E, Young GP et al (2010) Interval fecal immunochemical testing in a colonoscopic surveillance program speeds detection of colorectal neoplasia. Gastroenterology 139:1918–1926

    Article  PubMed  Google Scholar 

  27. Morris AM, Gryfe R, Thorson AG et al (2011) Canadian Association of General Surgeons, the American College of Surgeons, the Canadian Society of Colorectal Surgeons, and the American Society of Colorectal Surgeons: evidence based review in surgery – colorectal surgery. Dis Colon Rectum 54:1598–1600

    Article  Google Scholar 

  28. Engstrom PF, Arnoletti JP, Benson AP et al (2009) NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Cancer Netw 7:778–831

    Google Scholar 

  29. Criblez D (2007) Revidierte Konsensus-Empfehlungen zur Nachsorge nach koloskopischer Polypektomie und nach kurativ operiertem kolorektalem Karzinom. Schweiz Med Forum 7:994–999

    Google Scholar 

  30. Viehl CT, Ochsner A, von Holzen U et al (2010) Inadequate quality of surveillance after curative surgery for colon cancer. Ann Surg Oncol 17:2663–2669

    Article  PubMed  Google Scholar 

  31. Tsitikis VL, Maliraldy K, Green EA et al (2009) Postoperative surveillance recommendations for early stage colon cancer based on result from the clincal outcomes of surgical therapy trial. J Clin Oncol 27:3671–3676

    Article  Google Scholar 

  32. Desch CE, Benson AB III, Somerfield MR et al (2005) Colorectal Cancer Surveillance: 2005 Update of an American Society of Clinical Oncology Practice Guideline. J Clin Oncol 23:8512–8519

    Article  PubMed  Google Scholar 

  33. Fora A, Patta A, Attwood K et al (2012) Intensive radiographic and biomarker surveillance in stage II and III colorectal cancer. Oncology 82:41–47

    Article  CAS  PubMed  Google Scholar 

  34. Andreoni B, Chiappa A, Bertani E et al (2007) Surgical outcomes for colon and rectal cancer over a decade: results from a consecutive monocentric experience in 902 unselected patients. World J Surg Oncol 5:73

    Article  PubMed  Google Scholar 

  35. Jeffrey M, Hickey BE, Hider PN (2007) Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev CD002200

  36. Yakabe T, Nakafusa Y, Sumi K et al (2010) Clinical significance of CEA and CA19-9 in postoperative follow-up of colorectal cancer. Ann Surg Oncol 17:2349–2356

    Article  PubMed  Google Scholar 

  37. Chang GJ, Kaiser AM, Mills S et al (2012) Practice parameters for the management of colon cancer. Dis Colon Rectum 55:831–843

    Article  PubMed  Google Scholar 

  38. Borie F, Daures JP, Millat B et al (2004) Cost and effectiveness of follow-up examinations in patients with colorectal cancer resected for cure in a French population-based study. J Gastrointest Surg 8:552–558

    Article  PubMed  Google Scholar 

  39. Hara M, Sato M, Takahashi H et al (2010) Does serum Carcinoembryonic Antigen elevation in patients with postoperatve stage II colorectal cancer indicate recurrence ? Comparison with stage III. J Surg Oncol 102:154–157

    Article  PubMed  Google Scholar 

  40. Renehan AG, Egger M, Saunders MP et al (2002) Impact on survival of intensive follow-up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. Br Med J 324:813

    Article  Google Scholar 

  41. Holt A, Nelson RA, Lai L (2010) Surveillance with serial serum carcinoembryonic levels detect colorectal cancer recurrences in patients who are initial nonsecretors. Am Surg 76:1100–1103

    PubMed  Google Scholar 

  42. Mulder SA, Van Leerdam ME, Ouwendijk RJ et al (2007) Attendance at surveillance endoscopy of patients with adenoma or colorectal cancer. Scand J Gastroenterol 42:66–71

    Article  PubMed  Google Scholar 

  43. Herzlinger RE, Parsa-Parsi R (2004) Consumer-driven health care: lessons from Switzerland. JAMA 292:1213–1220

    Article  CAS  PubMed  Google Scholar 

  44. Grossmann I, de Bock GH, van de Velde et al (2007) Resalts of a national survey among Dutch surgeons treating patients with colorectal carcinoma. Current opinion about follow-up, treatment of metastasis, and reasons to revise follow-up practice. Colorect Dis 9:782–792

    Article  Google Scholar 

  45. Locker G, Hamilton S, Harris J et al (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24:5313–5327

    Article  CAS  PubMed  Google Scholar 

  46. Van der Geest LGM, Krijnen P, Wouters MWJM et al (2012) Improved guideline compliance after a 3-year audit of multidisciplinary colorectal cancer care in the western part of the Netherlands. J Surg Oncol 106:1–9

    Article  PubMed  Google Scholar 

  47. Ho JM, Juurlink DN, Cavalcanti RB (2010) Hypokalemia following polyethylene glycol-based bowel preparation for colonoscopy in older hospitalized patients with significant comorbidities. Ann Pharmacother 44:466–470

    Article  CAS  PubMed  Google Scholar 

  48. Miller A, Steele S (2012) Novell molecular screening approaches in corectal cancer. J Surg Oncol 105:459–467

    Article  CAS  PubMed  Google Scholar 

  49. Stoop EM, de Haan MC, de Wijkerslooth TR et al (2012) Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. Lancet Oncol 13:55–64

    Article  PubMed  Google Scholar 

  50. Barbas AS, Turley RS, Mantyh CR et al (2012) Effect of surgeon specialization on long-term survival following. Colon cancer resection at an NCI - designated cancer center. J Surg Oncol 106:219–223

    Article  PubMed  Google Scholar 

  51. Jones RP, Jackson R, Dunne DFJ et al (2012) Systematic review and meta-analysis of follow-up after hepatectomy for colorectal liver metastases. Br J Surg 99:477–486

    Article  CAS  PubMed  Google Scholar 

  52. Lyass S, Zamir G, Matot I et al (2001) Combined colon and hepatic resection for synchronous colorectal liver metastases. J Surg Oncol 78:17–21

    Article  CAS  PubMed  Google Scholar 

  53. Gomez D, Sangha VK, Morris-Stiff G (2010) Outcomes of intensive surveillance after resection of hepatic colorectal metastases. Br J Surg 97:1552–1560

    Article  CAS  PubMed  Google Scholar 

  54. Tarantino I, Warschkow R, Worni M et al (2012) Elevated preoperative CEA is associated with worse survival in stage I-III cancer patiens. Br J Cancer 107:266–274

    Article  CAS  PubMed  Google Scholar 

  55. Lin JK, Lin CC, Yang SH et al (2011) Early postoperative CEA level is a better prognostic indicator than is preoperative CEA level in predicting prognosis of patiens with curable colorectal cancer. Int J Colorectal Dis 26(9):1135–1141

    Article  PubMed  Google Scholar 

  56. Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95

    Article  Google Scholar 

  57. Saijo N (2012) Critical comments for roles of biomarkers. Cancer Treat Rev 38:63–67

    Article  CAS  PubMed  Google Scholar 

  58. Trapé J, Fiella X, Alsina-Donadeu et al (2011) Increased plasma concentrations of tumour markers in the absence of neoplasia. Clin Chem Lab Med 49(10):1605–1620

    Article  PubMed  Google Scholar 

  59. Canil CM, Tannok IF (2002) Doctor’s dilemma: incorporating tumor markers into clinical decision-making. Semin Oncol 29:286–293

    Article  PubMed  Google Scholar 

  60. Kern SE (2012) Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Ress 72(23):6097–6101

    Article  CAS  Google Scholar 

  61. Lecomte T, Ceze N, Dorval É et al (2010) Circulating free tumor DNA and colorectal cancer. Gastroen Clin Biol 34:662–681

    Article  CAS  Google Scholar 

  62. Ryan BM, Lefort F, McManus R et al (2003) A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperatve folow-up. Gut 52:101–108

    Article  CAS  PubMed  Google Scholar 

  63. Rose JS, Serna DS, Martin KL (2012) Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma. Cancer 118:6243–6252

    Article  CAS  PubMed  Google Scholar 

  64. De Vos T, Tetzner R, Model F et al (2009) Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 55:1337–1346

    Article  Google Scholar 

  65. Matsubara N (2012) Epigenetic regulation and colorectal cancer. Dis Colon Rectum 55:96–104

    Article  PubMed  Google Scholar 

  66. Cassinotti E, Melson J, Ligetti T et al (2012) DNA methylation patters in blood of patients with colorectal cancer and adenomatous colorectal polyps. Int J Cancer 131:1153–1157

    Article  CAS  PubMed  Google Scholar 

  67. Ahlquist DA, Zou H, Domanico M et al (2012) Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterol 142:248–256

    Article  CAS  Google Scholar 

  68. Miranda E, Bianchi P, Destro A et al (2013) Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases. Cancer 119:266–276

    Article  CAS  PubMed  Google Scholar 

  69. Baldus SE, Schaefer KL, Engels R et al (2010) Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16:790–799

    Article  CAS  PubMed  Google Scholar 

  70. Cohen SJ, Punt CJA, Iannotti N et al (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26:3213–3221

    Article  PubMed  Google Scholar 

  71. Lowes LE, Hegley BD, Keeney M et al (2012) User-defined protein marker assay development for characterization of circulating tumor cells using the Cell Search® System. Cytometry Part A 81A:983–995

    Article  CAS  Google Scholar 

  72. Sato N, Hayashi N, Imamura Y et al (2012) Usefulness of Transcription-Reserve Transcription Concerted reaction method for detecting ciculating tumor cells in patiens with colorectal cancer. Ann Surg Oncol 19:2060–2065

    Article  PubMed  Google Scholar 

  73. Flamini E, Mercatali L, Nanni O et al (2006) Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin Cancer Res 12:6985–6988

    Article  CAS  PubMed  Google Scholar 

  74. Phillipp AB, Stieber P, Nagel D et al (2012) Prognostic role of methylated free circulating DNA in colorectal cancer. Int J Cancer 131:2308–2319

    Article  Google Scholar 

  75. Chan C-C, Fan C-W, Kuo Y-B et al (2010) Multiple serological biomarkers for colorectal cancer detection. Int J Cancer 126:1683–1690

    Article  CAS  PubMed  Google Scholar 

  76. Lawrie CH, Gal S, Dunlop HM et al (2008) Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141:672–675

    Article  PubMed  Google Scholar 

  77. Huang Z, Huang D, Ni S et al (2010) Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 127:118–126

    Article  CAS  PubMed  Google Scholar 

  78. Brase J, Wuttig D, Kuner R et al (2010) Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 9:306

    Article  CAS  PubMed  Google Scholar 

  79. Shibuya H, Linuma H, Shimada R et al (2010) Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology 79:313–320

    Article  CAS  PubMed  Google Scholar 

  80. Nishida N, Yamashita S, Minori K et al (2012) MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-Fluorouracil in colorectal cancer cells. Ann Surg Oncol 19:3065–3071

    Article  PubMed  Google Scholar 

  81. Schwarzenbach H, Hoon DSB, Pantel K (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nature Rev/Cancer 11:426–436

    CAS  Google Scholar 

  82. Kosaka N, Iguchi H, Ochiya T (2010) Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 101:2087–2092

    Article  CAS  PubMed  Google Scholar 

  83. Mitchell PS, Parkin RK, Kroh EM et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci 105:10513–10518

    Article  CAS  PubMed  Google Scholar 

  84. Nair VS, Maeda LS, Ioannidis JPA (2012) Clinical outcome prediction by microRNAs in human cancer. A systematic review. Reviews/JNCI 104:528–540

    CAS  Google Scholar 

  85. Chen C, Ba Y, Ma L et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18:997–1006

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Institute of Oncology, Ráth György utca 7-9, 1122, Budapest, Hungary

    Enikő Orosz, László Tóth, Ádám Tarpay, Ákos Pap & Szabolcs Ottó

  2. Faculty of Medicine, Department of Public Health, University of Pécs, Pécs, Hungary

    István Ember & Katalin Gombos

Authors
  1. Enikő Orosz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. István Ember
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katalin Gombos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. László Tóth
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ádám Tarpay
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ákos Pap
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Szabolcs Ottó
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Szabolcs Ottó.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Orosz, E., Ember, I., Gombos, K. et al. Alternatives for the Intensive Follow-Up After Curative Resection of Colorectal Cancer. Potential Novel Biomarkers for the Recommendations. Pathol. Oncol. Res. 19, 619–629 (2013). https://doi.org/10.1007/s12253-013-9672-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-013-9672-7

Keywords

Search

Navigation